In the "3+3" dose escalation part of the study, participants will be enrolled sequentially into the 4 dose levels of SHR3162: 20 mg/day, 40 mg/day, 80 mg/day, and 120 mg/day (3 to 6 participants per cohort). Following the first dose, participants will have a single-dose pharmacokinetic (PK) run-in period (1-week treatment-free) to evaluate safety and single-dose PK. If no dose-limiting toxicities (DLTs) are observed during the 1-week period, SHR3162 administration will be resumed at the same dose level.